Alexander B. Olawaiye, MD

Alexander B. Olawaiye, MD, discusses future research directions with relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer.

Alexander B. Olawaiye, MD, discusses data with relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer that led to the phase 3 ROSELLA trial.

Alexander B. Olawaiye, MD, discusses clinical implications of data from the phase 3 ROSELLA trial.

Alexander Olawaiye, MD, presents results from the phase 3 ROSELLA trial, in which relacorilant combined with nab-paclitaxel significantly improved progression-free and overall survival vs nab-paclitaxel alone in patients with platinum-resistant ovarian cancer, with a manageable safety profile.

Alexander Olawaiye, MD, discusses the efficacy and safety of relacorilant plus nab-Paclitaxel in platinum-resistant ovarian cancer.

Alexander B. Olawaiye, MD, discusses future research that could inform the use of afuresertib plus paclitaxel in platinum-resistant ovarian cancer.

Alexander B. Olawaiye, MD, discusses how to address disparities in cancer care.

Alexander B. Olawaiye, MD, discusses front line treatment sequencing considerations in ovarian cancer.

Alexander B. Olawaiye, MD, discusses the social and biological determinants of disparities in women’s cancer.

Alexander Babatunde Olawaiye, MD, discusses the investigation of balstilimab plus zalifrelimab in gynecologic cancers.

Alexander B. Olawaiye, MD, discusses the role of surgery in women with newly diagnosed ovarian cancer.